24 June 2019 - The FDA made a mistake Friday by approving a new drug called Vyleesi for women with low sexual desire.
This is what happens when drug regulators lower — nearly to the floor — their own risk-benefit standards just so they can pander to special interests.
More on why FDA should have rejected Vyleesi in a moment. First, let’s deal with the Wall Street repercussions of this bad decision, starting with the inevitable, unsurprising but also undeserved jump in the stock price of Palatin Technologies.